Lloyd-JonesD,
AdamsRJ,
BrownTM.,
on behalf of the American Heart Association Statistics Committee and Stroke
Statistics Subcommittee. Heart disease and stroke statistics—2010
update: a report from the American Heart Association.
Circulation2010; 121:e46–215.
DOI
10.1161/CIRCULATIONAHA.109.192667
2.
RoseEA,
GeljinsAC,
MoskowitzAI.
Long-term use of a left ventricular assist device for
end-stage heart failure. N Engl J Med2001; 345:1435–43.
DOI 10.10567NEJMoa012175
3.
JenningsDL,
ChambersRM,
SchilligJM.
The pharmacotherapy of the HeartMate II, a continuous flow
left ventricular assist device, in patients with advanced heart failure:
integration of disease, device, and drug. Ann
Pharmacother2010; 44:1647–50.
DOI 10.1345/aph.1P340
4.
SlaughterMS,
PaganiFD,
RogersJG.
Clinical management of continuous-flow left ventricular
assist devices in advanced heart failure. J Heart
Lung Transplant2010; 29:Sl–39.
DOI
10.1016/j.healun.2010.01.011
5.
GastelurrutiaP,
BenrimojSI,
EspejoJ.
Negative clinical outcomes associated with drug-related
problems in heart failure outpatients: impact of a pharmacist in a
multidisciplinary HF clinic. J Cardiac Fail2011; 17:217–23.
DOI
10.1016/j.cardfail.2010.10.009
6.
KoshmanSL,
CharroisTL,
SimpsonSH,
McAlisterFA,
TsuyukiRT.
Pharmacist care of patients with heart failure: a systematic
review of randomized trials. Arch Intern
Med2008; 168:687–94.
DOI
10.1001/archinte.168.7.687
